[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiorgan-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiorgan-failure":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100634453",false,"NCT07539883","Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study","Official Title: Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study Using a Target Trial Emulation Approach","Inclusion Criteria:\n\n* Adults aged 19 years or older.\n* Admitted to the ICU with septic shock (Sepsis-3 criteria) between March 2021 and August 2025.\n* Required Continuous Renal Replacement Therapy (CRRT) due to acute kidney injury (AKI).\n\nExclusion Criteria:\n\n* Death or withdrawal of life-sustaining therapy within 48 hours of ICU admission.\n* Patients with End-Stage Renal Disease (ESRD).\n* Patients with missing critical covariates.","ALL","19 Years",{"count":18,"type":19},360,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.",[23,24,25],"Septic Shock","Multiorgan Failure","Sepsis",[27,28,29],"oXiris","Target Trial Emulation","Extracorporeal Blood Purification","RECRUITING","2026-04-13",{"date":33,"type":34},"2026-04-20","ACTUAL",{"date":36,"type":34},"2026-01-22",{"date":38,"type":19},"2026-12-31",{"name":40,"class":41},"Seoul National University Bundang Hospital","OTHER",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":42},"100442670","NCT05044403","Hemoperfusion in Critical Patients With Septic Multiorgan Dysfunction Syndrome.","Clinical Impact of Hemoperfusion With a Neutral Macroporous Resin Cartridge as Adjunctive Treatment in Septic Patients With Multiorgan Dysfunction Syndrome (MODS) Admitted to Intensive Care Units.","Inclusion Criteria:\n\n* Patients with a sepsis diagnosis, according to the diagnostic criteria of the International Sepsis-3 Consensus Conference, and without response to the treatment of septic shock who meet the following conditions:\n* Sepsis of abdominal origin with controlled infectious focus.\n* Noradrenaline dose\\> 0.5 µg \u002F kg \u002F min to maintain adequate organ perfusion after optimization of fluid therapy.\n* Dysfunction of two or more organs with SOFA ≥ 9 (5).\n* Blood lactate ≥ 2 mmol \u002F L.\n* Procalcitonin (PCT)\\> 10 ng \u002F mL.\n* CRP\\> 100 mg \u002F L.\n* IL-6\\> 2000 pg \u002F ml.\n\nExclusion Criteria:\n\n* Age under 18 years or over 80 years.\n* Pregnancy or breastfeeding.\n* Terminally ill patients or with a life expectancy of less than 48 hours.\n* Thrombocytopenia \\\u003C60,000 \u002F mm3.\n* Pancytopenia.\n* Severe coagulopathy with high risk of bleeding.\n* Inclusion in another research protocol.\n* In case of re-entry during the study period, only the first admission will be included.\n* Use of another haemoperfusion device.","18 Years","80 Years",{"count":52,"type":19},48,"INTERVENTIONAL",[55],"NA","Low-level interventional clinical trial to evaluate the effectiveness and safety of extracorporeal support with hemoperfusion in critical patients with septic multiorgan dysfunction syndrome.",[58,24,25],"Hemoperfusion","2025-06-04",{"date":61,"type":34},"2025-06-10",{"date":63,"type":34},"2023-03-01",{"date":65,"type":19},"2025-12-20",{"name":67,"class":41},"Hospital Clinic of Barcelona",{"id":69,"slug":4,"hasResults":10,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":10,"sex":15,"minAge":49,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100453219","NCT05181696","Retrospective Analysis of Chest X-ray Severity Scoring System of COVID-19 Pneumonia","Radiographic Severity Scoring System and Clinical and Laboratory Evolution of COVID-19 Pneumonia","RANCH-COVID","Inclusion Criteria:\n\n* Pneumonia caused by SARS-CoV-2 virus\n* Admission to the ICU COVID-19 unit\n\nExclusion Criteria:\n\n\\- Patients with lung tumors or history of lung resection","90 Years",{"count":77,"type":19},200,"The research will be retrospective, and will include all patients who were admitted during 2020 and 2021 in the COVID-19 ICU of University Hospital Center Osijek due to pneumonia caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of chest x-ray infiltrate evolution with changes in laboratory inflammatory parameters and respiratory function parameters will be examined.",[80,25,81,82,24],"COVID-19 Pneumonia","SARS-CoV-2 Acute Respiratory Disease","Pneumonia",[84,85,25,24,86,87],"COVID-19","Acute respiratory distress syndrome (ARDS)","Chest X-ray","Inflammation","2024-09-04",{"date":90,"type":34},"2024-09-19",{"date":92,"type":34},"2020-01-01",{"date":94,"type":19},"2025-05",{"name":96,"class":41},"Osijek University Hospital",""]